- XML
- PDF 505.64 K
- Supplementary File
- 11.final (188-195).pdf
Abstract
Abstract:
Background:
Obesity is a widespread health issue worldwide, marked by long-lasting, low-level inflammation and resistance to insulin. Procalcitonin (PCT) has been recognized as a probable indicator of inflammation linked to obesity, given that high levels of PCT in the blood are strongly associated with measures of fatness and insulin resistance. Nevertheless, the exact role of PCT in insulin resistance remains uncertain.
Objectives:
The study aims to provide insights into the role of PCT in obesity-related inflammation and evaluate its potential as a diagnostic tool for insulin resistance.
Methods:
The study included 120 subjects with obesity and insulin resistance, and 80 control group. The study also included anthropometric measurements (BMI, WC, and blood pressure) and laboratory tests (fasting serum insulin, fasting serum glucose, and plasma procalcitonin).
Results:
In the study, 120 patients diagnosed with obesity were compared to 80 controls. The research found that the average level of procalcitonin (PCT) was significantly higher in obese patients (P <0.05) when compared to the control group. Specifically, the mean PCT level in obese patients was 0.122±0.168 ng/ml, while in controls, it was 0.086±0.0047 ng/ml. The analysis also showed a significant correlation between PCT and insulin resistance, as measured by HOMA-IR, with a Pearson correlation coefficient of 0.187 and a (P-value 0.040).
Conclusion: The study found that the mean level of procalcitonin (PCT) was significantly higher in patients with obesity and insulin resistance compared to controls.
Keywords
Main Subjects
)
